Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas.
Lymphoma is a heterogeneous group of diseases with many curable subtypes. Primary treatment cures a significant proportion of, but not all, patients. Patients not achieving a complete remission with primary treatment, or those who relapse later, have a second chance of cure with high-dose chemotherapy and haematopoietic stem cell transplantation. Response assessment is therefore crucial in the management of lymphomas. FDG-PET has an emerging role in assessing response, both at the end of and during treatment. This article will review the current published evidence and offer some suggestions on future directions from a clinician's viewpoint.
Mikhaeel
N George
NG
Department of Clinical Oncology, Guy's and St. Thomas' Hospital, London, SE1 7EH, UK. george.mikhaeel@gstt.nhs.uk
D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000532:radiotherapy*; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012074:Remission Induction; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18